The effect of atorvastatin on the treatment of secondary pulmonary hypertension

Evaluation of the effect of atorvastatin on the treatment of secondary pulmonary hypertension due to chronic obstructive air way diseases

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201108257411N1

Enrollment

Registered

2012-05-20

Start date

2009-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

secondary pulmonary hypertension. Chronic lower respiratory diseases

Interventions

Intervention 1: Tab atorvastatin 20 mg BID (twice a day) in case group. Intervention 2: placebo in control group.

Treatment - Drugs

Placebo

Tab atorvastatin 20 mg BID (twice a day) in case group

placebo in control group

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Systolic pulmonary hypertension>40mmhg; age 18 years or over until 80; no drug history of prostanoids, statins, endothelin antagonists and phosphodiesterase; able to doing 6-min walk test; obstructive pattern in PFT and functional class 2,3 (NYHA). Exclusion criteria: PAH from a cause other COPD; LDL 3x ULN.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Systolic pulmonary hypertension. Timepoint: At the beginning of study and 6 months later. Method of measurement: Echocardiography.	—

Secondary

Measure	Time frame
CRP. Timepoint: At the beginning of study and 6 months later. Method of measurement: Lab data.;Cardiac output. Timepoint: At the beginning of study and 6 months later. Method of measurement: Echocardiography.;Right ventricular size. Timepoint: At the beginning of study and 6 months later. Method of measurement: Echocardiography.;6 min walk test. Timepoint: At the beginning of study and 6 months later. Method of measurement: By researcher.;FEV1, FVC, FEV1/FVC. Timepoint: At the beginning of study and 6 months later. Method of measurement: Spirometry.;Adverse effect of drug. Timepoint: One month after beginning and the end of treatment. Method of measurement: By lab data and symptoms.	—

Measure

Time frame

CRP. Timepoint: At the beginning of study and 6 months later. Method of measurement: Lab data.;Cardiac output. Timepoint: At the beginning of study and 6 months later. Method of measurement: Echocardiography.;Right ventricular size. Timepoint: At the beginning of study and 6 months later. Method of measurement: Echocardiography.;6 min walk test. Timepoint: At the beginning of study and 6 months later. Method of measurement: By researcher.;FEV1, FVC, FEV1/FVC. Timepoint: At the beginning of study and 6 months later. Method of measurement: Spirometry.;Adverse effect of drug. Timepoint: One month after beginning and the end of treatment. Method of measurement: By lab data and symptoms.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Seied Alijavad Moosavi

Tehran university of medical sciences

Dr_moosavi_pul@yahoo.ca+98 21 4465 9771

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 22, 2026